Search

Your search keyword '"Lasset, C"' showing total 2,965 results

Search Constraints

Start Over You searched for: "Lasset, C" Remove constraint "Lasset, C"
2,965 results on '"Lasset, C"'

Search Results

102. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

103. Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

104. Uptake of genetic counseling among adult children of BRCA1/2 mutation carriers in France.

105. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.

106. A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL)

107. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma‐prone families from three continents

108. [Identification and management of HNPCC syndrome (hereditary non polyposis colon cancer), hereditary predisposition to colorectal and endometrial adenocarcinomas]

109. Common BRCA2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA1 Mutation Carriers

110. HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles.

111. [Gender-specific differences in the development of colorectal cancer in Lynch syndrome patients-A systematic review].

112. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.

114. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.

115. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

116. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

117. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

118. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

119. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)

120. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2

121. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers

122. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

123. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

124. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

125. Neurofibromatosis and early onset of cancers in hMLH1-deficient children

126. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk prediction

127. GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.

128. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].

129. Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer.

130. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.

131. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.

132. Bibliometric analysis of a century of research on oral erythroplakia and leukoplakia.

133. MULTIVARIATE ANALYSIS OF RISK FACTORS IN STAGE IV NEUROBLASTOMA PATIENTS OVER THE AGE OF ONE YEAR TREATED WITH MEGATHERAPY AND STEM CELL TRANSPLANTATION: A REPORT FROM THE EUROPEAN BONE MARROW TRANSPLANTATION SOLID TUMOR REGISTRY

137. Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families

144. [Considerations on the organization of oncologic-genetic consultations (a first step towards the publication of clinical practice guidelines)]

145. OT2-04-03: Uptake of a Randomized Breast Cancer Prevention Trial Comparing Letrozole to Placebo in BRCA1/2 Mutations Carriers: The FNCLCC ONCO-03/LIBER Trial.

150. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation

Catalog

Books, media, physical & digital resources